- Home
- LXEH vs PRPH Comparison
LXEH vs PRPH Comparison
Compare LXEH & PRPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXEH | PRPH |
|---|---|---|
| Founded | 2001 | 1989 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 6.0M |
| IPO Year | 2020 | 1997 |
Fundamental Metrics
Financial Performance| Metric | LXEH | PRPH |
|---|---|---|
| Price | $0.23 | $0.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 189.8K | ★ 21.6M |
| Earning Date | 12-30-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $4,585,942.00 | ★ $5,055,000.00 |
| Revenue This Year | N/A | $221.82 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.22 | $0.08 |
| 52 Week High | $50.08 | $0.93 |
Technical Indicators
Market Signals| Indicator | LXEH | PRPH |
|---|---|---|
| Relative Strength Index (RSI) | 26.63 | 24.11 |
| Support Level | $0.27 | $0.11 |
| Resistance Level | $0.31 | $0.12 |
| Average True Range (ATR) | 0.02 | 0.02 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 14.95 | 8.37 |
Price Performance
Historical ComparisonAbout LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About PRPH ProPhase Labs Inc. (DE)
ProPhase Labs Inc is a diversified company offering various services, including diagnostic testing, genomics testing, and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers, and government organizations. The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of OTC consumer healthcare products and dietary supplements in the United States. It also provides personal genomics products and services.